Читать книгу Anti-Aging Therapeutics Volume XIII - A4M American Academy - Страница 37

The nutritional program outlined above, the B-Sit/AOX Matrix, has been used for over 5-years, and the results reported in the first section are based on this use. Visually, this can be seen in Figure 1, which shows imaging results of the same prostate, initially diagnosed as a Gleason 7 (image a) and upon a follow-up examine after daily use of the above supplement regime (image b).

The results shown in Figure 1 illustrate both the efficacy of restoring fundamental nutritional support that has been systematically removed from our diets by alterations in the food supply, and the need for a means to monitor, on a regular basis, each individual’s response to treatment. Given the number of factors involved in nutritional support, this is the only way to know that this individual’s body is capable of restoring its anti-cancer functions. The same monitoring approach can be applied to any therapeutic intervention, especially since the 3-D sonogram is not compromised by the treatment itself.

Figure 1. Prostate cancer subject treated with B-Sit/AOX supplement program. a) DCE-MRI of Gleason 7 non-palpable prostate cancer (yellow arrow), (vascular enhancement is red), b) Post treatment scan of same area showing disappearance of vascular enhancement.

When establishing a monitoring schedule for an individual, two additional areas need to be kept in mind, interval cancers and evaluating successful treatment. The concept of fast growing cancers called “interval cancers” has led to routine biannual screening of male and female high risk patients. It is recognized that mammography misses invasive breast cancers with great frequency, so there is a half-year time period in which health conscious women should alert themselves to the possibility of early breast cancer as they routinely undergo ultrasound breast screening twice a year. In practice, about 5% of men develop aggressive interval cancers within half a year from their last normal or stable evaluation. A presentation entitled “Interval Cancers of the Prostate: Evaluation By 3-T MRI and 3-D Power Doppler Ultrasound” was made at the 2009 meeting of the Societe Francaises de Radiologie in Paris demonstrating that new aggressive tumors may occur more rapidly than clinically expected and may, in part, explain the failure of certain treatments.

When a man has not had a biopsy or has had a negative biopsy and a vascular tumor is demonstrated on the 3-D PDS, an MRI exam is recommended, which shows the prostate gland, the capsule of the prostate, the regional lymph glands, seminal vesicles, and boney pelvis. Other bones, to which cancer frequently spreads, such as the lower spine and hip, may also be imaged for abnormalities. While the MRI exam is not as good an indicator of cancer aggression, it shows spread of the tumor outside the prostate capsule to the lymph nodes better then the 3-D PDS and better than the CT scan, which is currently used as the standard test for staging.